All research
Equities & sectorsFranklin Templeton Standout

Three Forces Carrying Biotech into 2027

ChinaArtificial intelligence

Our summary

Biotech is entering 2027 with improving economics, expanding scientific opportunity and returning capital, while share prices in several cases still lag the sector's progress.

  • AI is already helping drug developers select laboratory experiments and prepare regulatory documentation faster, while AI-designed molecules have reached late-stage trials and newer target-discovery platforms could reach initial human validation within two to three years.
  • Chinese biotech companies are moving candidates into human trials faster than many Western peers, and pharmaceutical companies are increasingly licensing Chinese assets to replenish pipelines after patent expirations.
  • Laboratory suppliers report recovering research demand, with one large supplier's orders ahead of sales and another raising its outlook because of a stronger backlog; Chinese spending is recovering while remaining below its 2021–2022 peak.
  • Cell therapies are showing promise in lupus and other autoimmune diseases, a bladder cancer treatment is approaching regulatory filing, and GLP-1 medicines are reaching more lower-income Americans through Medicaid.
  • Biopharma M&A value had already exceeded the full-year 2025 total by September 30, 2026, supported by pharmaceutical patent expirations and mid-sized biotech companies using product-launch cash to acquire pipeline assets.

Takeaway: Investors should look beyond cautious sentiment and disclosed pipelines because improving research activity, new therapies and deal demand may support biotech valuations, although drug-pricing policy, financing conditions and clinical setbacks remain material risks.

Published by Franklin Templeton. Summary by HF Best Ideas.

More from Franklin Templeton

Latest research

Share this summary